JUNE Medical Announces the Launch of a Male Surgical Retractor Kit

October 13, 2020

JUNE Medical is expanding its comprehensive portfolio of medical devices with the upcoming launch of its new pre-packed retractor kits, especially for male procedures. Based on the company’s award-winning Galaxy II retractor, the Galaxy II Male kit brings the same level of innovation to male surgeries.

June Medical notes the Galaxy II Male kit is set to revolutionize male procedures by dramatically improving visualization during surgery. This straightforward and easy to use kit is suitable for a wide range of procedures requiring optimal control over the surgical site, such as scrotal and associated surgeries, as well as prosthetic testicle implantations. The kit features a number of different accessories and a novel hammock elevation strap to maneuver the male anatomy, allowing the penis to be held securely without requiring hooks through the skin, improving patient comfort.

The kit also benefits from all of the characteristics that have made the Galaxy II system so popular. The retractor’s unique, design-protected cam locks allow simple single-handed adjustment for rapid repositioning, while the slots on the retractor ring easily secure the stays in place. Together with a range of stay hooks designed to enable high tension without the risk of tissue tearing, this system provides an innovative, cost-effective, and convenient solution for a wide range of surgical procedures.

Angela Spang, CEO of JUNE Medical, commented: “The Galaxy II frees up the hands of assistants and nurses that often have to hold the retractor, sometimes for long periods of time. This improves efficiency and reduces the number of people needed in the operating room, which is especially useful during the COVID-19 pandemic to help reduce infection risk.”

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.

By using this website you agree to accept Medical Device News Magazine Privacy Policy